JP7357133B2 - 蛍光トレーサ剤の非侵襲的モニタリングのためのセンサヘッド - Google Patents
蛍光トレーサ剤の非侵襲的モニタリングのためのセンサヘッド Download PDFInfo
- Publication number
- JP7357133B2 JP7357133B2 JP2022168214A JP2022168214A JP7357133B2 JP 7357133 B2 JP7357133 B2 JP 7357133B2 JP 2022168214 A JP2022168214 A JP 2022168214A JP 2022168214 A JP2022168214 A JP 2022168214A JP 7357133 B2 JP7357133 B2 JP 7357133B2
- Authority
- JP
- Japan
- Prior art keywords
- light
- photodetector
- light source
- signal
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012544 monitoring process Methods 0.000 title description 43
- 230000005284 excitation Effects 0.000 claims description 146
- 238000005259 measurement Methods 0.000 claims description 129
- 238000001514 detection method Methods 0.000 claims description 82
- 238000012937 correction Methods 0.000 claims description 72
- 230000003907 kidney function Effects 0.000 claims description 39
- 230000000694 effects Effects 0.000 claims description 37
- 238000007781 pre-processing Methods 0.000 claims description 32
- 238000012545 processing Methods 0.000 claims description 31
- 238000004364 calculation method Methods 0.000 claims description 19
- 230000006870 function Effects 0.000 claims description 18
- 238000003705 background correction Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 238000012952 Resampling Methods 0.000 claims description 10
- 238000011067 equilibration Methods 0.000 claims description 7
- 230000024924 glomerular filtration Effects 0.000 claims description 7
- 238000001647 drug administration Methods 0.000 claims description 6
- 230000035790 physiological processes and functions Effects 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 230000008542 thermal sensitivity Effects 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 description 123
- 239000003795 chemical substances by application Substances 0.000 description 109
- 210000001519 tissue Anatomy 0.000 description 94
- 238000000034 method Methods 0.000 description 87
- 210000003491 skin Anatomy 0.000 description 82
- 238000005286 illumination Methods 0.000 description 46
- 230000000670 limiting effect Effects 0.000 description 30
- 230000000875 corresponding effect Effects 0.000 description 26
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 239000000463 material Substances 0.000 description 21
- 238000010521 absorption reaction Methods 0.000 description 20
- 238000010586 diagram Methods 0.000 description 18
- 238000000926 separation method Methods 0.000 description 18
- 230000008859 change Effects 0.000 description 17
- 230000015654 memory Effects 0.000 description 17
- 239000000853 adhesive Substances 0.000 description 16
- 230000001070 adhesive effect Effects 0.000 description 16
- 239000011521 glass Substances 0.000 description 15
- 108010054147 Hemoglobins Proteins 0.000 description 14
- 102000001554 Hemoglobins Human genes 0.000 description 14
- 230000007423 decrease Effects 0.000 description 14
- XHNJXRDGTITISI-QWWZWVQMSA-N (2r)-2-[[3,6-diamino-5-[[(1r)-1-carboxy-2-hydroxyethyl]carbamoyl]pyrazine-2-carbonyl]amino]-3-hydroxypropanoic acid Chemical compound NC1=NC(C(=O)N[C@H](CO)C(O)=O)=C(N)N=C1C(=O)N[C@H](CO)C(O)=O XHNJXRDGTITISI-QWWZWVQMSA-N 0.000 description 12
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 230000005855 radiation Effects 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 239000007850 fluorescent dye Substances 0.000 description 9
- 230000003595 spectral effect Effects 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 238000000354 decomposition reaction Methods 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 238000000295 emission spectrum Methods 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000013307 optical fiber Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 230000023077 detection of light stimulus Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 239000012780 transparent material Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
- 238000000862 absorption spectrum Methods 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000010703 silicon Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 230000036962 time dependent Effects 0.000 description 5
- 239000004593 Epoxy Substances 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 238000001506 fluorescence spectroscopy Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000031700 light absorption Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001360 synchronised effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000013021 overheating Methods 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000000411 transmission spectrum Methods 0.000 description 3
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 241000511976 Hoya Species 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 101150018840 SPM1 gene Proteins 0.000 description 2
- 101100335888 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GAL83 gene Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 150000003216 pyrazines Chemical class 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- CORFWQGVBFFZHF-UHFFFAOYSA-N 2-iodohippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1I CORFWQGVBFFZHF-UHFFFAOYSA-N 0.000 description 1
- VELGYJCKWFALBF-UHFFFAOYSA-N 3,6-diaminopyrazine-2,5-dicarboxylic acid Chemical class NC1=NC(C(O)=O)=C(N)N=C1C(O)=O VELGYJCKWFALBF-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 229910000838 Al alloy Inorganic materials 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000872198 Serjania polyphylla Species 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 108010002255 deoxyhemoglobin Proteins 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000012799 electrically-conductive coating Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- AMGQUBHHOARCQH-UHFFFAOYSA-N indium;oxotin Chemical compound [In].[Sn]=O AMGQUBHHOARCQH-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229940029378 iothalamate Drugs 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/20—Measuring for diagnostic purposes; Identification of persons for measuring urological functions restricted to the evaluation of the urinary system
- A61B5/201—Assessing renal or kidney functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7228—Signal modulation applied to the input signal sent to patient or subject; demodulation to recover the physiological signal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J1/00—Photometry, e.g. photographic exposure meter
- G01J1/02—Details
- G01J1/04—Optical or mechanical part supplementary adjustable parts
- G01J1/0488—Optical or mechanical part supplementary adjustable parts with spectral filtering
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J1/00—Photometry, e.g. photographic exposure meter
- G01J1/42—Photometry, e.g. photographic exposure meter using electric radiation detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J1/00—Photometry, e.g. photographic exposure meter
- G01J1/42—Photometry, e.g. photographic exposure meter using electric radiation detectors
- G01J1/44—Electric circuits
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/02—Details
- G01J3/027—Control of working procedures of a spectrometer; Failure detection; Bandwidth calculation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/02—Details
- G01J3/10—Arrangements of light sources specially adapted for spectrometry or colorimetry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
- G01J3/44—Raman spectrometry; Scattering spectrometry ; Fluorescence spectrometry
- G01J3/4406—Fluorescence spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6408—Fluorescence; Phosphorescence with measurement of decay time, time resolved fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0223—Operational features of calibration, e.g. protocols for calibrating sensors
- A61B2560/0228—Operational features of calibration, e.g. protocols for calibrating sensors using calibration standards
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J1/00—Photometry, e.g. photographic exposure meter
- G01J1/42—Photometry, e.g. photographic exposure meter using electric radiation detectors
- G01J1/44—Electric circuits
- G01J2001/4446—Type of detector
- G01J2001/4453—PMT
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/4738—Diffuse reflection, e.g. also for testing fluids, fibrous materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2201/00—Features of devices classified in G01N21/00
- G01N2201/06—Illumination; Optics
- G01N2201/062—LED's
- G01N2201/0625—Modulated LED
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Description
本出願は、2017年1月30日出願の米国特許仮出願第62/452、021号に基づく優先権を主張するものである。上記出願の開示内容は、参照により本明細書中に援用される。
本開示は、一般的に、光の散乱及び/または吸収によって特徴付けられる媒体内の蛍光トレーサ剤の非侵襲的モニタリング方法に関する。より詳細には、本開示は、患者の組織内の外因性蛍光トレーサのクリアランスをインビボでモニタリングすることによる腎機能の非侵襲的評価方法に関する。
Claims (19)
- 患者の腎機能の測定値をリアルタイムで表示するためのシステムであって、
前記患者に配置された少なくとも1つのセンサヘッドから測定データセットを受信するように構成されたコントローラであって、
前記少なくとも1つのセンサヘッドから複数の信号を受信するように構成された取得ユニットと、
前記複数の信号に補正を適用し、補正された複数の信号の一部を腎機能の尺度に変換するように構成された処理ユニットであって、(i)補正された前記複数の信号の平衡後部分を特定するように構成された薬剤投与後選択サブユニットと、(ii)患者の腎機能を示す腎低下時定数(RDTC)を計算するために、前記平衡後部分において得られた補正された複数の信号を変換するように構成されたRDTC計算サブユニットとを有し、前記平衡後部分は、前記補正された複数の信号の、対数変換されたときに蛍光信号の線形減衰を表す時間領域を含む、該処理ユニットと、
を有する、該コントローラと、
前記RDTC計算サブユニットによって生成されたRDTCを表示するように構成された表示ユニットとを備える、システム。 - 請求項1に記載のシステムであって、
前記薬剤投与後選択サブユニットは、前記平衡後部分を特定し、前記RDTC計算サブユニットに知らせるように構成される、システム。 - 請求項1に記載のシステムであって、
前記RDTC計算サブユニットは、RDTCを糸球体濾過率(GFR)に変換して前記患者の腎機能を定量化するように構成される、システム。 - 請求項1に記載のシステムであって、
前記RDTC計算サブユニットは、計算されたRDTCを、時間の関数としてのRDTCのグラフ、単一の離散RDTC値、時間の関数としてのRDTC値のテーブル、色分けされた表示、または前記計算されたRDTCを正常/健康、異常、高、低、及び任意の他の適切な分類として分類可能か否かを特定するように構成された他の表示フォーマットのいずれかの表示フォーマットで提供するように構成される、システム。 - 請求項4に記載のシステムであって、
前記フォーマットは連続的または非連続的に更新される、システム。 - 請求項1に記載のシステムであって、
前記RDTC計算サブユニットは、前記測定データセットにおける、互いに重なっていないウィンドウ、及び互いに重なったウィンドウ内でRDTCを計算するように構成される、システム。 - 請求項1に記載のシステムであって、
前記表示ユニットは、グラフィカルユーザインターフェースを含む、システム。 - 請求項1に記載のシステムであって、
前記コントローラは、前記少なくとも1つのセンサヘッドの少なくとも1つの光源を操作するように構成された光源制御ユニットをさらに含む、システム。 - 請求項1に記載のシステムであって、
前記コントローラは、前記少なくとも1つのセンサヘッドの少なくとも1つの光検出器を操作するように構成された光検出器制御ユニットをさらに含む、システム。 - 請求項1に記載のシステムであって、
前記処理ユニットは、信号アーチファクトを除去するために前記複数の信号を決定及び補正するように構成された前処理サブユニットをさらに含む、システム。 - 請求項10に記載のシステムであって、
前記前処理サブユニットは、前記患者の生理学的プロセスに関連する信号のばらつきを低減するように構成されたリサンプリングモジュールを含む、システム。 - 請求項10に記載のシステムであって、
前記前処理サブユニットは、前記少なくとも1つのセンサヘッドの少なくとも1つの光検出器の熱感受性を補償する温度補正を可能にするように構成された検出器温度補正モジュールを含む、システム。 - 請求項10に記載のシステムであって、
前記前処理サブユニットは、前記患者の組織の不均一性に関連する検出信号のばらつきに対する補正を可能にするように構成された組織不均一性補正モジュールを含む、システム。 - 請求項10に記載のシステムであって、
前記前処理サブユニットは、前記複数の信号に対して励起光漏出減算を実行するように構成された励起光漏出減算モジュールを含む、システム。 - 請求項10に記載のシステムであって、
前記前処理サブユニットは、前記複数の信号に対して蛍光漏出減算を実行するように構成された蛍光漏出減算モジュールを含む、システム。 - 請求項1に記載のシステムであって、
前記処理ユニットは、自家蛍光及び光漏出の影響を補正するために、前記複数の信号からベースライン信号を減算するように構成されたベースライン減算サブユニットをさらに含む、システム。 - 請求項1に記載のシステムであって、
前記処理ユニットは、自家蛍光及び光漏出の変化に関連する背景信号の動的変化の影響を除去するように構成された背景補正サブユニットをさらに含む、システム。 - 請求項1に記載のシステムであって、
前記処理ユニットは、前記複数の信号の大きさをモニタリングして前記システムの異常を検出するように構成された障害検出サブユニットをさらに含む、システム。 - 請求項18に記載のシステムであって、
前記障害検出サブユニットは、前記表示ユニットを介して、前記システム内で検出された障害である異常を通知するように構成される、システム。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762452021P | 2017-01-30 | 2017-01-30 | |
US62/452,021 | 2017-01-30 | ||
JP2019541064A JP7165137B2 (ja) | 2017-01-30 | 2018-01-30 | 背景分離補正を用いた蛍光トレーサ剤の非侵襲的モニタリングのためのシステム |
PCT/US2018/016053 WO2018140984A1 (en) | 2017-01-30 | 2018-01-30 | Method for non-invasive monitoring of fluorescent tracer agent with background separation corrections |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019541064A Division JP7165137B2 (ja) | 2017-01-30 | 2018-01-30 | 背景分離補正を用いた蛍光トレーサ剤の非侵襲的モニタリングのためのシステム |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023011691A JP2023011691A (ja) | 2023-01-24 |
JP7357133B2 true JP7357133B2 (ja) | 2023-10-05 |
Family
ID=62977380
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019541064A Active JP7165137B2 (ja) | 2017-01-30 | 2018-01-30 | 背景分離補正を用いた蛍光トレーサ剤の非侵襲的モニタリングのためのシステム |
JP2022168214A Active JP7357133B2 (ja) | 2017-01-30 | 2022-10-20 | 蛍光トレーサ剤の非侵襲的モニタリングのためのセンサヘッド |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019541064A Active JP7165137B2 (ja) | 2017-01-30 | 2018-01-30 | 背景分離補正を用いた蛍光トレーサ剤の非侵襲的モニタリングのためのシステム |
Country Status (16)
Country | Link |
---|---|
US (1) | US10194854B2 (ja) |
EP (1) | EP3574255A4 (ja) |
JP (2) | JP7165137B2 (ja) |
KR (1) | KR102316452B1 (ja) |
CN (2) | CN110476051B (ja) |
AU (1) | AU2018212019B2 (ja) |
BR (1) | BR112019015561B1 (ja) |
CA (1) | CA3051857A1 (ja) |
IL (1) | IL268333B (ja) |
MX (1) | MX2019009028A (ja) |
MY (1) | MY196727A (ja) |
PH (1) | PH12019501748A1 (ja) |
RU (2) | RU2020113620A (ja) |
SG (1) | SG11201906937YA (ja) |
WO (1) | WO2018140984A1 (ja) |
ZA (1) | ZA201904972B (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016145119A1 (en) * | 2015-03-09 | 2016-09-15 | Spectrasensors, Inc. | Intrinsically safe spectroscopic analyzer |
WO2019133837A1 (en) * | 2017-12-28 | 2019-07-04 | University Of Notre Dame Du Lac | Super-resolution fluorescence microscopy by stepwise optical saturation |
JP7387720B2 (ja) | 2018-05-03 | 2023-11-28 | アコヤ・バイオサイエンシズ・インコーポレイテッド | マルチスペクトルサンプル画像化 |
US11781964B2 (en) * | 2020-05-05 | 2023-10-10 | Becton, Dickinson And Company | Methods for determining detector gain in a flow cytometer |
GB2597521A (en) * | 2020-07-27 | 2022-02-02 | Sensor Coating Systems Ltd | Detection system and method |
WO2022216778A1 (en) * | 2021-04-06 | 2022-10-13 | Berkeley Lights, Inc. | Methods of microfluidic assay and bioproduction from non-mammalian cells and kits therefor |
CN115728276B (zh) * | 2022-11-14 | 2024-01-23 | 中船重工安谱(湖北)仪器有限公司 | 爆炸物检测方法和检测系统 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004517041A (ja) | 2000-07-19 | 2004-06-10 | ザ ジェネラル ホスピタル コーポレーション | 有機官能基の実時間測定のための蛍光剤 |
JP2011521899A (ja) | 2008-04-18 | 2011-07-28 | ファーマコフォトニクス,インコーポレイティド | 腎機能の分析方法及び装置 |
US20140275869A1 (en) | 2013-03-14 | 2014-09-18 | Profusa, Inc. | Method and device for correcting optical signals |
JP2017502706A (ja) | 2013-10-22 | 2017-01-26 | ハインリッヒ,ラルフ | 改善された経皮臓器機能測定 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5591981A (en) * | 1995-03-16 | 1997-01-07 | Bio-Rad Laboratories, Inc. | Tunable excitation and/or tunable emission fluorescence imaging |
AU2001250287B2 (en) * | 2000-04-11 | 2005-06-23 | Chemometec A/S | Method and apparatus for detecting fluorescence of a sample |
US6733744B1 (en) | 2000-10-16 | 2004-05-11 | Mallinckrodt Inc. | Indole compounds as minimally invasive physiological function monitoring agents |
RU2190208C2 (ru) * | 2000-12-14 | 2002-09-27 | Государственный научно-исследовательский институт биологического приборостроения | Устройство для измерения люминесценции биологических образцов |
US6697652B2 (en) * | 2001-01-19 | 2004-02-24 | Massachusetts Institute Of Technology | Fluorescence, reflectance and light scattering spectroscopy for measuring tissue |
US20030215391A1 (en) * | 2001-07-19 | 2003-11-20 | Carlos Rabito | Fluorescent agents for real-time measurement of organ function |
AU2005280455A1 (en) | 2004-08-26 | 2006-03-09 | Mallinckrodt Inc. | Luminescent metal complexes for monitoring renal function |
GB0426993D0 (en) | 2004-12-09 | 2005-01-12 | Council Cent Lab Res Councils | Apparatus for depth-selective raman spectroscopy |
US20080277595A1 (en) | 2007-05-10 | 2008-11-13 | Pacific Biosciences Of California, Inc. | Highly multiplexed confocal detection systems and methods of using same |
US20110028806A1 (en) | 2009-07-29 | 2011-02-03 | Sean Merritt | Reflectance calibration of fluorescence-based glucose measurements |
US8314377B2 (en) * | 2009-12-23 | 2012-11-20 | Mcneil-Ppc, Inc. | Device and method for detecting plaque in the oral cavity |
EP4160192B1 (en) * | 2010-01-25 | 2024-05-29 | University Health Network | Device, system and method for quantifying fluorescence and optical properties |
US8818733B2 (en) * | 2010-04-20 | 2014-08-26 | Mayo Foundation For Medical Education And Research | Determination of photodynamic therapy (PDT) treatment parameters |
GB201014837D0 (en) * | 2010-09-07 | 2010-10-20 | Immunovia Ab | Biomarker signatures and uses thereof |
US9155473B2 (en) * | 2012-03-21 | 2015-10-13 | Korea Electrotechnology Research Institute | Reflection detection type measurement apparatus for skin autofluorescence |
US10080484B2 (en) * | 2014-01-31 | 2018-09-25 | University Of Washington | Multispectral wide-field endoscopic imaging of fluorescence |
-
2018
- 2018-01-30 AU AU2018212019A patent/AU2018212019B2/en active Active
- 2018-01-30 SG SG11201906937YA patent/SG11201906937YA/en unknown
- 2018-01-30 JP JP2019541064A patent/JP7165137B2/ja active Active
- 2018-01-30 MX MX2019009028A patent/MX2019009028A/es unknown
- 2018-01-30 EP EP18745216.4A patent/EP3574255A4/en active Pending
- 2018-01-30 CA CA3051857A patent/CA3051857A1/en active Pending
- 2018-01-30 US US15/884,371 patent/US10194854B2/en active Active
- 2018-01-30 KR KR1020197024777A patent/KR102316452B1/ko active IP Right Grant
- 2018-01-30 MY MYPI2019004346A patent/MY196727A/en unknown
- 2018-01-30 RU RU2020113620A patent/RU2020113620A/ru unknown
- 2018-01-30 WO PCT/US2018/016053 patent/WO2018140984A1/en unknown
- 2018-01-30 BR BR112019015561-9A patent/BR112019015561B1/pt active IP Right Grant
- 2018-01-30 RU RU2019127183A patent/RU2720132C1/ru active
- 2018-01-30 CN CN201880009056.XA patent/CN110476051B/zh active Active
- 2018-01-30 CN CN202210535866.7A patent/CN114965401A/zh active Pending
- 2018-01-30 IL IL268333A patent/IL268333B/en unknown
-
2019
- 2019-07-29 PH PH12019501748A patent/PH12019501748A1/en unknown
- 2019-07-29 ZA ZA2019/04972A patent/ZA201904972B/en unknown
-
2022
- 2022-10-20 JP JP2022168214A patent/JP7357133B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004517041A (ja) | 2000-07-19 | 2004-06-10 | ザ ジェネラル ホスピタル コーポレーション | 有機官能基の実時間測定のための蛍光剤 |
JP2011521899A (ja) | 2008-04-18 | 2011-07-28 | ファーマコフォトニクス,インコーポレイティド | 腎機能の分析方法及び装置 |
US20140275869A1 (en) | 2013-03-14 | 2014-09-18 | Profusa, Inc. | Method and device for correcting optical signals |
JP2017502706A (ja) | 2013-10-22 | 2017-01-26 | ハインリッヒ,ラルフ | 改善された経皮臓器機能測定 |
Also Published As
Publication number | Publication date |
---|---|
ZA201904972B (en) | 2022-05-25 |
EP3574255A1 (en) | 2019-12-04 |
BR112019015561A2 (pt) | 2020-03-17 |
KR102316452B1 (ko) | 2021-10-26 |
CN110476051B (zh) | 2022-09-27 |
WO2018140984A1 (en) | 2018-08-02 |
CA3051857A1 (en) | 2018-08-02 |
RU2720132C1 (ru) | 2020-04-24 |
JP2020507372A (ja) | 2020-03-12 |
PH12019501748A1 (en) | 2020-06-01 |
US20180214062A1 (en) | 2018-08-02 |
SG11201906937YA (en) | 2019-08-27 |
US10194854B2 (en) | 2019-02-05 |
MX2019009028A (es) | 2019-12-11 |
NZ755760A (en) | 2021-03-26 |
CN114965401A (zh) | 2022-08-30 |
JP2023011691A (ja) | 2023-01-24 |
RU2020113620A (ru) | 2020-09-25 |
AU2018212019A1 (en) | 2019-08-15 |
EP3574255A4 (en) | 2020-12-09 |
AU2018212019B2 (en) | 2020-05-07 |
IL268333A (en) | 2019-09-26 |
IL268333B (en) | 2022-07-01 |
KR20190107123A (ko) | 2019-09-18 |
MY196727A (en) | 2023-05-03 |
BR112019015561B1 (pt) | 2023-12-12 |
CN110476051A (zh) | 2019-11-19 |
JP7165137B2 (ja) | 2022-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7263425B2 (ja) | 拡散反射補正を用いた蛍光トレーサ剤の非侵襲的モニタリングのためのセンサヘッド | |
JP7357133B2 (ja) | 蛍光トレーサ剤の非侵襲的モニタリングのためのセンサヘッド | |
NZ755760B2 (en) | Method for non-invasive monitoring of fluorescent tracer agent with background separation corrections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221021 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221021 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221124 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230614 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230829 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230905 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230925 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7357133 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |